Protocol Ledger

NCT06182774 · Phase III · RECRUITING

Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

Interventional Phase III clinical trial protocol NCT06182774 sponsored by Canadian Cancer Trials Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-04-10 Enrollment: 570 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06182774
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)570 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06182774
Protocol FieldVerified Registry Value
NCT IdentifierNCT06182774
Consolidated Lead SponsorCanadian Cancer Trials Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment570 participants (ESTIMATED)
Registered Start Date2024-04-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06182774
Hospital Research SiteLocationSite Profile
Cross Cancer InstituteEdmonton, CanadaOpen Hospital Dossier ->
CancerCare ManitobaWinnipeg, CanadaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI